Pazopanib: A multikinase inhibitor with activity in advanced renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 5, 2010, Pages 635-645

  Bukowski, Ronald M ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Pazopanib; Renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLT3 LIGAND; GEMCITABINE; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PACLITAXEL; PAZOPANIB; PEMETREXED; PROTEIN RET; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VOTRIENT;

ADVANCED CANCER; ANEMIA; ANGIOGENESIS; CANCER GROWTH; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHANGIOGENESIS; LYMPHOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BLEEDING; UNITED STATES; VEIN THROMBOSIS; VOMITING;

ANIMALS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES;

EID: 77952483702     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.38     Document Type: Review

References (33)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA. Cancer J. Clin. 58, 71-96 (2008).
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
3. Young AC, Craven RA, Cohen D et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin. Cancer Res. 15 (24), 7582-7592 (2009).
4. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl. J. Med. 349, 419-421 (2003). Excellent review of the VHL gene and its role in clear-cell carcinoma.
5. Rini BI. Vascular endothelial growth factor targeted therapy in metastatic renal cell carcinoma. Cancer 115, 2306-2312 (2009).
6. Sternberg CN, Davis I, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. doi/10.1200/JCO.2009.23.9764 (2010) (Epub ahead of print). Pivotal Phase III pazopanib trial.
7. Castaneda CA, Gomez HL. Pazopanib: an antiangiogenic drug in perspective. Future Oncol. 5 (9), 1335-1348 (2009).
8. Cao Y, Zhong W. Tumor derived lymph angiogenic factors and lymphatic metastases. Biomed. Pharmacother. 61, 534-539 (2007).
9. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat. Rev. Clin. Oncol. 6, 395-404 (2009).
10. Harris PA, Cheung M, Hunter RN et al. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR-2 kinase inhibitors. J. Med. Chem. 48, 1610-1619 (2005). (Pubitemid 40364567)
11. Harris PA, Boloor A, Cheung M et al. Discovery of 5-[[4-[(2, 3-Dimethyl-2H-indazol-6-yl) methylamino] -2 pyrimidinyl] amino] 2 methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632-4640 (2008). Study describing the original synthesis of pazopanib.
12. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6 (7), 2012-2021 (2007). Interesting preclinical study of the pharmacodynamics of pazopanib.
13. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
14. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 1-9 (2009).
15. Kumar R, Crouthamel MC, Rominger DH et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101, 1717-1723 (2009).
16. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib (GW786034), an oral multikinase angiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activity. Clin. Cancer Res. 15, 4220-4227 (2009). Initial Phase I trial of pazopanib in solid tumor patients.
17. ™: full prescribing information, October (2009).
18. Tan AR, Jones SF, Dowlati A et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). J. Clin. Oncol 26 (Suppl.), (2008) (Abstract 3552).
19. Suttle B, Jones SF, Dowlati A et al. Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034). J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 18S (20 Suppl.), 14118 (2007).
20. Brady J, Middelton M, Midgley RS et al. A Phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer. J. Clin. Oncol. 15s (Suppl.), 27 (2009) (Abstract 4133).
21. Frentzas SN, Groves MD, Barriuso J et al. Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study. J. Clin. Oncol. 15s (Suppl.), 27 (2009) (Abstract 2040).
22. Dejonge M, Savage S, Verweij J et al. A Phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 18S (20 Suppl.), 3088 (2006).
23. Feldman D, Baum M, Ginsberg M et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1432-1439 (2009).
24. Rini BI, Garcia JA, Cooney MM et al. A Phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin. Cancer Res. 15 (19), 6277-6283 (2009).
25. Hutson TE, Davis ID, Machiels JH et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 475-480 (2010). Phase II randomized discontinuation trial of pazopanib in advanced renal cell carcinoma.
26. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370, 2103-2111 (2007). (Pubitemid 350296300)
27. Motzer RJ, Bacik J, Murphy BA et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002).
28. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
29. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
30. IMS MIDAS (IMS Health) (2009).
31. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenibrefractory metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4462-4468 (2009).
32. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoima reveals inactivation of histone modifying genes. Nature DOI: 10.1038/nature08672 (2010) (Epub ahead of print).
33. Bukowski RM, Yasthan U, Kirkpatrick P. Pazopanib. Nat. Rev. Drug Discov. 9, 1-2 (2010).